Opendata, web and dolomites

DIALYBRID

Revolutionising the world of hemodialysis with a novel, hybrid, silk fibroin/polyurethane vascular access

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 DIALYBRID project word cloud

Explore the words cloud of the DIALYBRID project. It provides you a very rough idea of what is the project "DIALYBRID" about.

blend    manufactured    million    silk    people    human    patients    limitations    soundness    live    54m    consequence    reducing    therapy    frequent    industrialization    alternatives    innovative    health    semidegradable    competitiveness    jobs    functioning    complications    clinical    life    ip    arteriovenous    opportunity    diversify    increment    delivering       hypertension    trl    fibroin    certification    business    graft    fact    create    bottleneck    sme    reg    longer    hemodialysis    470    master    turnover    diabetes    society    suffer    viability    msca    validation    scenario    worldwide    2025    frequency    proposes    venture    plan    silkothane    skilled    view    polyurethane    technological    infective    patency    cannulation    enter    productivity    costly    granting    risk    sustaining    placement    sag    auspices    revolutionize    renal    accesses    reached    nanostructured    action    38    verify    market    global    ftes    hybrid    re    interventions    portfolio    commercialization    de    vascular    remodeling    28    integration    2030    meet    saving    36    members    commercial    quality    urgent    electrospinning    trademarked    materials    bel   

Project "DIALYBRID" data sheet

The following table provides information about the project.

Coordinator
BIOENGINEERING LABORATORIES 

Organization address
address: VIA VIVALDI 32/A
city: CANTU'
postcode: 22063
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.bioengineeringlab.com/eng/sme-instrument-phase-1-dialybrid-december-1-2018/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIOENGINEERING LABORATORIES IT (CANTU') coordinator 50˙000.00

Map

 Project objective

Vascular access is the bottleneck to long-term hemodialysis for about 2.2 million people worldwide who need this life-saving/life-sustaining therapy in case of renal failure, e.g. as a consequence of diabetes and/or hypertension. The current alternatives of vascular access suffer in fact from several limitations, e.g. the need for frequent and costly re-interventions, reduced patency, infective complications. To meet this urgent, global, clinical need, BEL proposes SAG (Silkothane® Arteriovenous Graft), an innovative, hybrid, semidegradable, nanostructured vascular access, manufactured by electrospinning using Silkothane®, a silk fibroin/polyurethane blend developed and trademarked by BEL under the auspices of a MSCA action. Enabling early cannulation and easy placement, as well as remodeling, patency, and integration on the long term, SAG will revolutionize the scenario of hemodialysis vascular accesses worldwide by: reducing the frequency of complications and re-interventions (thus health costs); granting broader access to hemodialysis; improving the patients’ quality of life, enabling them to live longer as functioning members of the society. SAG has reached TRL 6. Phase 1 would allow BEL to verify the soundness of SAG’s venture (with a Business Plan and an IP Management Plan), and to de-risk the technological viability of the industrialization (delivering Essential Requirements, Risk Analysis, Validation Master Plan, Industrialization Plan), in view of future clinical studies, certification and commercialization. SAG represents for BEL an important opportunity to diversify its product portfolio, enter the market of Advanced Materials, experience growth in productivity and competitiveness and create new jobs. As the commercial potential of SAG is estimated to be around 28 million € in 2025 and 54M€ in 2030, in 2025 the SME would experience an increment in turnover of about 470%, and a 36% increase (from 28 FTEs to 38 FTEs) in highly skilled human resources.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DIALYBRID" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DIALYBRID" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Totem Spoon (2019)

Interactive Digital Signage with emotional intelligence for smart cities

Read More  

MycoProScale (2020)

MycoProScale – Creating global markets with a unique large-scale Mycorrhiza production method

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More